CN114222741B - 作为p2x3抑制剂的吡啶并嘧啶类衍生物 - Google Patents
作为p2x3抑制剂的吡啶并嘧啶类衍生物Info
- Publication number
- CN114222741B CN114222741B CN202080038831.1A CN202080038831A CN114222741B CN 114222741 B CN114222741 B CN 114222741B CN 202080038831 A CN202080038831 A CN 202080038831A CN 114222741 B CN114222741 B CN 114222741B
- Authority
- CN
- China
- Prior art keywords
- pyrimidin
- pyrido
- amine
- fluorophenyl
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19177610.3 | 2019-05-31 | ||
| EP19177610 | 2019-05-31 | ||
| EP19201165.8 | 2019-10-02 | ||
| EP19201165 | 2019-10-02 | ||
| PCT/EP2020/064915 WO2020239953A1 (en) | 2019-05-31 | 2020-05-28 | Pyridopyrimidines derivatives as p2x3 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114222741A CN114222741A (zh) | 2022-03-22 |
| CN114222741B true CN114222741B (zh) | 2025-12-30 |
Family
ID=70857198
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080038831.1A Active CN114222741B (zh) | 2019-05-31 | 2020-05-28 | 作为p2x3抑制剂的吡啶并嘧啶类衍生物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12606562B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3976609A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7797204B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102923602B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN114222741B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020281924B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021020279A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3136024A1 (cg-RX-API-DMAC7.html) |
| MA (1) | MA56020A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021014116A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020239953A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA56022A (fr) | 2019-05-31 | 2022-04-06 | Chiesi Farm Spa | Dérivés d'amino quinazoline servant d'inhibiteurs de p2x3 |
| KR102923602B1 (ko) | 2019-05-31 | 2026-02-06 | 키에시 파르마슈티시 엣스. 피. 에이. | P2x3 억제제로서 피리도피리미딘 유도체 |
| WO2022160931A1 (zh) * | 2021-01-28 | 2022-08-04 | 浙江海正药业股份有限公司 | 吡啶并嘧啶类衍生物及其制备方法和用途 |
| JP2026517300A (ja) | 2023-05-22 | 2026-05-28 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | P2x3阻害剤を調製するための方法および中間体 |
| WO2026143058A1 (en) * | 2024-12-23 | 2026-07-02 | Neolaia Inc. | Pyridopyrimidine compounds useful as cd38 inhibitors |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011041655A1 (en) * | 2009-10-01 | 2011-04-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Quinazolin-4-amine derivatives; and methods of use |
| CN109641886A (zh) * | 2015-11-25 | 2019-04-16 | 康威基内有限公司 | 双环bet布罗莫结构域抑制剂及其用途 |
| CN112739699A (zh) * | 2018-07-25 | 2021-04-30 | 费斯制药股份有限公司 | 作为组胺h4受体抑制剂的吡啶并嘧啶化合物 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH31122A (en) | 1993-03-31 | 1998-02-23 | Eisai Co Ltd | Nitrogen-containing fused-heterocycle compounds. |
| JP4342007B2 (ja) * | 1998-08-10 | 2009-10-14 | 大日本住友製薬株式会社 | キナゾリン誘導体 |
| PT1725540E (pt) | 2004-03-05 | 2012-11-29 | Hoffmann La Roche | Diaminopirimidinas como antagonistas de p2x3 e p2x2/3 |
| SI1924264T1 (sl) * | 2005-09-01 | 2013-12-31 | F. Hoffmann-La Roche Ag | Diaminopirimidini kot modulatorji p2x3 in p2x2/3 |
| WO2007134986A1 (en) | 2006-05-23 | 2007-11-29 | F. Hoffmann-La Roche Ag | Pyridopyrimidinone derivatives |
| ES2596706T3 (es) | 2006-06-29 | 2017-01-11 | F. Hoffmann-La Roche Ag | Arilamidas con sustitución de tetrazol |
| TW200840584A (en) | 2006-12-26 | 2008-10-16 | Gilead Sciences Inc | Pyrido(3,2-d)pyrimidines useful for treating viral infections |
| WO2008123963A1 (en) | 2007-04-02 | 2008-10-16 | Renovis, Inc. | Pyrid-2-yl fused heterocyclic compounds, and compositions and uses thereof |
| US8076345B2 (en) | 2007-04-17 | 2011-12-13 | Evotec Ag | 2-cyanophenyl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine compounds, compositions and uses thereof |
| WO2009110985A2 (en) | 2008-02-29 | 2009-09-11 | Renovis, Inc. | Amide compounds, compositions and uses thereof |
| US20110237578A1 (en) | 2008-09-18 | 2011-09-29 | Zhi-Liang Wei | Amide compounds, compositions and uses thereof |
| JP2012504157A (ja) | 2008-09-30 | 2012-02-16 | アストラゼネカ アクチボラグ | 複素環式jakキナーゼ阻害剤 |
| SG173647A1 (en) | 2009-02-13 | 2011-10-28 | Shionogi & Co | Novel triazine derivative and pharmaceutical composition containing same |
| WO2012064973A2 (en) * | 2010-11-10 | 2012-05-18 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| EP2938600B1 (en) | 2012-12-27 | 2017-01-25 | F. Hoffmann-La Roche AG | Comt inhibitors |
| WO2016053794A1 (en) | 2014-09-30 | 2016-04-07 | Bristol-Myers Squibb Company | Quinazoline-based kinase inhibitors |
| WO2016084922A1 (ja) | 2014-11-28 | 2016-06-02 | 塩野義製薬株式会社 | 1,2,4-トリアジン誘導体およびその医薬組成物 |
| WO2016088838A1 (ja) | 2014-12-04 | 2016-06-09 | 塩野義製薬株式会社 | プリン誘導体およびその医薬組成物 |
| CU24411B1 (es) | 2014-12-09 | 2019-05-03 | Bayer Ag | Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos |
| WO2017011729A1 (en) | 2015-07-16 | 2017-01-19 | Patara Pharma, LLC | Combination therapies for the treatment of lung diseases |
| CA2998742C (en) | 2015-09-29 | 2023-08-29 | Anthony P. FORD | Diaminopyrimidine p2x3 and p2x2/3 receptor modulators for use in the treatment of cough |
| CN106565684B (zh) | 2016-03-18 | 2019-06-18 | 南方医科大学 | 6-吡唑取代喹唑啉类化合物及其衍生物、合成方法及其应用 |
| JP6776378B2 (ja) | 2016-06-30 | 2020-10-28 | ギリアード サイエンシーズ, インコーポレイテッド | Cotモジュレーターとしての4,6−ジアミノキナゾリン類およびその使用方法 |
| GB201700814D0 (en) * | 2017-01-17 | 2017-03-01 | Liverpool School Tropical Medicine | Compounds |
| TWI762634B (zh) | 2017-05-05 | 2022-05-01 | 大陸商上海赫普化醫藥技術有限公司 | 胺基-芳基-苯甲醯胺化合物及其使用方法 |
| CN109721554A (zh) | 2019-01-08 | 2019-05-07 | 贵州大学 | 一类4-氨基喹唑啉类化合物及其制备方法和应用 |
| MA56022A (fr) * | 2019-05-31 | 2022-04-06 | Chiesi Farm Spa | Dérivés d'amino quinazoline servant d'inhibiteurs de p2x3 |
| KR102923602B1 (ko) | 2019-05-31 | 2026-02-06 | 키에시 파르마슈티시 엣스. 피. 에이. | P2x3 억제제로서 피리도피리미딘 유도체 |
-
2020
- 2020-05-28 KR KR1020217038473A patent/KR102923602B1/ko active Active
- 2020-05-28 EP EP20728500.8A patent/EP3976609A1/en active Pending
- 2020-05-28 CN CN202080038831.1A patent/CN114222741B/zh active Active
- 2020-05-28 MA MA056020A patent/MA56020A/fr unknown
- 2020-05-28 MX MX2021014116A patent/MX2021014116A/es unknown
- 2020-05-28 JP JP2021571021A patent/JP7797204B2/ja active Active
- 2020-05-28 AU AU2020281924A patent/AU2020281924B2/en active Active
- 2020-05-28 WO PCT/EP2020/064915 patent/WO2020239953A1/en not_active Ceased
- 2020-05-28 CA CA3136024A patent/CA3136024A1/en active Pending
- 2020-05-28 BR BR112021020279A patent/BR112021020279A2/pt unknown
- 2020-05-28 US US17/615,012 patent/US12606562B2/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011041655A1 (en) * | 2009-10-01 | 2011-04-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Quinazolin-4-amine derivatives; and methods of use |
| CN109641886A (zh) * | 2015-11-25 | 2019-04-16 | 康威基内有限公司 | 双环bet布罗莫结构域抑制剂及其用途 |
| CN112739699A (zh) * | 2018-07-25 | 2021-04-30 | 费斯制药股份有限公司 | 作为组胺h4受体抑制剂的吡啶并嘧啶化合物 |
Non-Patent Citations (4)
| Title |
|---|
| Evaluation of substituted 6-arylquinazolin-4-amines as potent and selective inhibitors of cdc2-like kinases (Clk);Bryan T. Mott等;《Bioorganic & Medicinal Chemistry Letters》;20091003;第19卷;第6700-6705页 * |
| Ju Hou等.Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor.《European Journal of Medicinal Chemistry》.2016,第118卷第276-289页. * |
| Potent and selective small molecule inhibitors of specific isoforms of Cdc2-like kinases (Clk) and dual specificity tyrosine-phosphorylation-regulated kinases (Dyrk);Andrew S. Rosenthal等;《Bioorganic & Medicinal Chemistry Letters》;20110304;第21卷;第3152-3158页 * |
| RN2062039-46-5等化合物;ACS;《REGISTRY(STN)》;20170131;第1-5页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021020279A2 (pt) | 2021-12-14 |
| US20220235060A1 (en) | 2022-07-28 |
| EP3976609A1 (en) | 2022-04-06 |
| JP2022534434A (ja) | 2022-07-29 |
| WO2020239953A1 (en) | 2020-12-03 |
| MX2021014116A (es) | 2021-12-10 |
| AU2020281924B2 (en) | 2026-04-16 |
| KR102923602B1 (ko) | 2026-02-06 |
| MA56020A (fr) | 2022-04-06 |
| US12606562B2 (en) | 2026-04-21 |
| AU2020281924A1 (en) | 2021-12-16 |
| KR20220016074A (ko) | 2022-02-08 |
| US20230212169A9 (en) | 2023-07-06 |
| CA3136024A1 (en) | 2020-12-03 |
| JP7797204B2 (ja) | 2026-01-13 |
| CN114222741A (zh) | 2022-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114269432B (zh) | 作为p2x3抑制剂的氨基喹唑啉衍生物 | |
| JP7797204B2 (ja) | P2x3阻害剤としてのピリドピリミジン誘導体 | |
| CN116745284A (zh) | 作为p2x3抑制剂的酞嗪衍生物 | |
| EP4251617B1 (en) | (aza)quinoline 4-amines derivatives as p2x3 inhibitors | |
| RU2833037C2 (ru) | Производные пиридопиримидинов в качестве ингибиторов p2x3 | |
| HK40060820B (en) | Pyridopyrimidines derivatives as p2x3 inhibitors | |
| HK40060820A (zh) | 作为p2x3抑制剂的吡啶并嘧啶类衍生物 | |
| HK40091208A (en) | Phthalazine derivatives as p2x3 inhibitors | |
| HK40106991A (en) | Amino quinazoline derivatives as p2x3 inhibitors | |
| HK40062196B (en) | Amino quinazoline derivatives as p2x3 inhibitors | |
| HK40088660A (en) | (aza)quinoline 4-amines derivatives as p2x3 inhibitors | |
| HK40057265B (en) | Amino quinazoline derivatives as p2x3 inhibitors | |
| AU2024357784A1 (en) | Compounds and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40060820 Country of ref document: HK |
|
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |